To MMP or not to MMP: A role for matrix metalloproteinase 3 in primary sclerosing cholangitis?

Liver International

Volumn 31, Issue 6, 2011, Pages 751-754

  Folseraas, Trine ^a   Karlsen, Tom H ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; INTERLEUKIN 1BETA; MULTIDRUG RESISTANCE PROTEIN 2; STROMELYSIN;

CHRONIC INFLAMMATION; COLLAGEN SYNTHESIS; DEGRADATION KINETICS; DISEASE COURSE; DISEASE SEVERITY; EDITORIAL; ENTERITIS; EXTRACELLULAR MATRIX; FIBROSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; INTRAHEPATIC BILE DUCT; NONHUMAN; SCLEROSING CHOLANGITIS; STELLATE CELL;

CHOLANGITIS, SCLEROSING; COLITIS, ULCERATIVE; COMORBIDITY; DISEASE PROGRESSION; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MATRIX METALLOPROTEINASE 3; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK ASSESSMENT; RISK FACTORS;

EID: 79958049721     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02471.x     Document Type: Editorial

References (20)

1. Karlsen TH, Schrumpf E, Boberg KM. Update on primary sclerosing cholangitis. Dig Liver Dis 2010; 42: 390-400.
2. Ludwig J, MacCarty RL, LaRusso NF, Krom RA, Wiesner RH. Intrahepatic cholangiectases and large-duct obliteration in primary sclerosing cholangitis. Hepatology 1986; 6: 560-8.
3. Popov Y, Patsenker E, Fickert P, Trauner M, Schuppan D. Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol 2005; 43: 1045-54.
4. Hemmann S, Graf J, Roderfeld M, Roeb E. Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol 2007; 46: 955-75.
5. Juran BD, Atkinson EJ, Schlicht EM, et al. Genetic polymorphisms of matrix metalloproteinase 3 in primary sclerosing cholangitis. Liver Int 2011; 31: 787-93.
6. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004; 4: 617-29.
7. Knittel T, Mehde M, Kobold D, et al. Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-alpha and TGF-beta1. J Hepatol 1999; 30: 48-60.
8. Louis E, Ribbens C, Godon A, et al. Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease. Clin Exp Immunol 2000; 120: 241-6.
9. Mora B, Bonamico M, Ferri M, et al. Association of the matrix metalloproteinase-3 (MMP-3) promoter polymorphism with celiac disease in male subjects. Hum Immunol 2005; 66: 716-20.
10. Hinoda Y, Okayama N, Takano N, et al. Association of functional polymorphisms of matrix metalloproteinase (MMP)-1 and MMP-3 genes with colorectal cancer. Int J Cancer 2002; 102: 526-9.
11. Satsangi J, Chapman RW, Haldar N, et al. A functional polymorphism of the stromelysin gene (MMP-3) influences susceptibility to primary sclerosing cholangitis. Gastroenterology 2001; 121: 124-30.
12. Wiencke K, Louka AS, Spurkland A, et al. Association of matrix metalloproteinase-1 and -3 promoter polymorphisms with clinical subsets of Norwegian primary sclerosing cholangitis patients. J Hepatol 2004; 41: 209-14.
13. Ye S, Eriksson P, Hamsten A, et al. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem 1996; 271: 13055-60.
14. Maeda S, Dean DD, Gomez R, Schwartz Z, Boyan BD. The first stage of transforming growth factor beta1 activation is release of the large latent complex from the extracellular matrix of growth plate chondrocytes by matrix vesicle stromelysin-1 (MMP-3). Calcif Tissue Int 2002; 70: 54-65.
15. Schonbeck U, Mach F, Libby P. Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol 1998; 161: 3340-6.
16. Cameron RG, Blendis LM, Neuman MG. Accumulation of macrophages in primary sclerosing cholangitis. Clin Biochem 2001; 34: 195-201.
17. Karrar A, Broome U, Sodergren T, et al. Biliary epithelial cell antibodies link adaptive and innate immune responses in primary sclerosing cholangitis. Gastroenterology 2007; 132: 1504-14.
18. Karlsen TH, Melum E, Franke A. The utility of genome-wide association studies in hepatology. Hepatology 2010; 51: 1833-42.
19. Houle D, Govindaraju DR, Omholt S. Phenomics: the next challenge. Nat Rev Genet 2010; 11: 855-66.
20. Karlsen TH, Hov JR. Genetics of cholestatic liver disease in 2010. Curr Opin Gastroenterol 2010; 26: 251-8.